This HTML5 document contains 147 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://dx.doi.org/10.1111/
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q50703280
rdf:type
wikibase:Item
schema:description
2007年学术文章 2007年学术文章 научни чланак 2007年學術文章 мақолаи илмӣ artigo científico vitenskapelig artikkel articol științific 2007년 논문 teaduslik artikkel artykuł naukowy научна статия επιστημονικό άρθρο scientific article published in March 2007 bilimsel makale 2007年学术文章 artikull shkencor 2007年學術文章 vetenskaplig artikel scientific article published in March 2007 vitskapeleg artikkel 2007 nî lūn-bûn artículu científicu wissenschaftlicher Artikel videnskabelig artikel 2007年學術文章 2007年学术文章 სამეცნიერო სტატია article scientific artigo científico tudományos cikk 2007年の論文 articolo scientifico scienca artikolo tieteellinen artikkeli vědecký článek artikel ilmiah 2007年学术文章 artículo científico publicado en 2007 مقالة علمية نشرت في مارس 2007 научни чланак 2007年學術文章 bài báo khoa học article científic artigo científico মার্চ ২০০৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научная статья article scientifique scientific article published in March 2007 2007年學術文章 2007年学术文章 наукова стаття, опублікована в березні 2007 wetenschappelijk artikel บทความทางวิทยาศาสตร์ vedecký článok artikulong pang-agham מאמר מדעי naučni članak
p:P577
wds:Q50703280-A29A5500-26F1-45CC-902A-318B5A3A81E3
wdt:P577
2007-03-01T00:00:00Z
p:P407
wds:Q50703280-1D3168E4-06C1-45BF-9366-8BCA4E7F3973
wdt:P407
wd:Q1860
p:P2860
wds:Q50703280-90B2B14A-CB38-49C0-BE61-0790F2F4C919 wds:Q50703280-ABCD6CAA-FA74-4391-AAB5-88EC83F18315 wds:Q50703280-AC06A130-CEBA-4CFF-AA22-20EC0A78DF19 wds:Q50703280-C7409F1F-1A63-443A-89AA-5D32CDFC9921 wds:Q50703280-CC41DDDF-91DB-409C-B828-5EB00F50A566 wds:Q50703280-34D92CEC-758E-415D-9EBA-7C5118A9F065 wds:Q50703280-36B9D179-1218-4199-BD4E-98D83FEE3D91 wds:Q50703280-3C638BCE-78B4-428E-9CF1-6B0447E21A4F wds:Q50703280-501F7E6F-F460-48ED-984E-E68EF3403FF8 wds:Q50703280-6266825F-470B-4E6C-BE4D-16310EC3A8D2 wds:Q50703280-6CC37E8C-2FB4-4E0E-874D-D70FFA24623D wds:Q50703280-78D3FCCA-A4FC-4FDA-8EE1-1AD85CC00C98 wds:Q50703280-82E88552-B7AC-44FD-9682-D452880BCF28 wds:Q50703280-F2A18C4F-3EB7-49C3-ADF5-F88D28A0024E wds:Q50703280-050C1A1D-54C2-4180-8598-9BE0D4E94DE0 wds:Q50703280-0982D59F-886C-41C1-AF17-FB0DE5DE03BE wds:Q50703280-0986AFB6-CC17-4417-8197-C5C8810DD90D
wdt:P2860
wd:Q44161639 wd:Q24569561 wd:Q44201018 wd:Q34402999 wd:Q45053450 wd:Q33339181 wd:Q44743783 wd:Q33370863 wd:Q33349757 wd:Q52012542 wd:Q35555698 wd:Q28255301 wd:Q33358665 wd:Q33363871 wd:Q43863967 wd:Q33371863 wd:Q25938997
p:P2093
wds:Q50703280-5292B85B-6859-4CB8-BB3C-D9738D1E97FA
wdt:P2093
Deborah A Thomas
rdfs:label
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
skos:prefLabel
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
schema:name
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
p:P50
wds:Q50703280-15604E99-BF9E-4749-AA8C-7C7650FCAEB7 wds:Q50703280-1CC23C4E-E8ED-47F8-80EF-9F6B1D45D05D wds:Q50703280-232BBD32-88C9-45F2-B205-56A09BD155B7 wds:Q50703280-816EB79D-80B5-47F3-BAF8-A4A5506A6064 wds:Q50703280-7B1C16D3-90FB-4D7F-88A5-B8F46DC1B132 wds:Q50703280-300FF390-5C63-4D53-8A1A-DE73FFC5842A wds:Q50703280-D18DECE7-D027-45EF-A2B2-AC821FB290EF wds:Q50703280-C8A80E5F-BB80-4A47-A423-A0627F0BF663
wdt:P50
wd:Q66429891 wd:Q62066745 wd:Q66370727 wd:Q64026278 wd:Q60394812 wd:Q66370731 wd:Q60320900 wd:Q66429598
p:P1476
wds:Q50703280-DF6DAE49-200B-41E3-A11F-258A2EC127F0
wdt:P1476
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
p:P304
wds:Q50703280-8B98DD7A-2298-4CC3-BE19-03CA9E9060A6
wdt:P304
800-805
p:P31
wds:Q50703280-4880F262-FC3E-4DAD-8DC1-61CB1816FBC0
wdt:P31
wd:Q13442814
p:P921
wds:Q50703280-A72CF813-CD07-4F03-B3A0-1752FDFE5CD4 wds:Q50703280-8014C86D-41D9-4C7D-BD9E-9CFB16129512 wds:Q50703280-DF78543A-4719-4F29-8E3B-DBADDD73DA13
wdt:P921
wd:Q1088156 wd:Q29496 wd:Q715347
p:P698
wds:Q50703280-8ABD7111-14A1-4B4E-B494-7940157A83D6
wdtn:P698
n9:17341265
wdt:P698
17341265
p:P1433
wds:Q50703280-C3ED84ED-7929-4C21-956D-D28EEB9FDE58
wdt:P1433
wd:Q4970200
p:P433
wds:Q50703280-99B110B4-6221-422B-B7AE-DCB3C5706189
p:P478
wds:Q50703280-AC9F1AFD-3884-406F-BCFC-45A90FB1DBC0
wdt:P433
6
wdt:P478
136
p:P356
wds:Q50703280-54D4F8A2-1C38-4428-B922-060B75A7BD72
wdtn:P356
n11:J.1365-2141.2007.06513.X
wdt:P356
10.1111/J.1365-2141.2007.06513.X
p:P5875
wds:Q50703280-C3E89EE8-A335-4E92-A701-6F89BAF38FBD
wdt:P5875
6466046